• Home
  • About us
  • News
  • Strategic considerations for implementing the revised EMA guideline on FIH clinical trials

Strategic considerations for implementing the revised EMA guideline on FIH clinical trials

First-in-human trial?

Zwiers Regulatory Consultancy is proud to have contributed to the article: “Strategic considerations for implementing the revised EMA guideline on FIH clinical trials” in the special June issue of TOPRA Regulatory Rapporteur on Clinical Trials.

Find out how to implement the updated EMA guideline in your strategy; check out the Regulatory Rapporteur

Regulatory Rapporteur is available to download for TOPRA members.